CYP2D6 phenotype and the metabolism of nicotine and cotinine

被引:23
|
作者
Benowitz, NL
Jacob, P
PerezStable, E
机构
[1] UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA
[2] UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA
来源
PHARMACOGENETICS | 1996年 / 6卷 / 03期
关键词
nicotine; cotinine; metabolism; CYP2D6;
D O I
10.1097/00008571-199606000-00006
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
That CYP2D6 activity is an important determinant of nicotine metabolism and that people who have abnormal CYP2D6 genes are poor metabolizers of nicotine has been reported in the medical literature. The aim of this study was to assess the role of CYP2D6 in nicotine metabolism, Specifically, we compared the clearance of stable isotope-labelled nicotine and cotinine in 11 poor and 33 extensive metabolizers of dextromethorphan, a probe for CYP2D6 activity, The groups were matched by gender, age and ethnicity, Nicotine and cotinine kinetics were quite similar for cases and controls, These data suggest that CYP2D6 is nob a major isozyme for the metabolism of nicotine or cotinine.
引用
收藏
页码:239 / 242
页数:4
相关论文
共 50 条
  • [1] Nicotine metabolism and CYP2D6 phenotype in smokers
    Caporaso, NE
    Lerman, C
    Audrain, J
    Boyd, NR
    Main, D
    Issaq, HJ
    Utermahlan, B
    Falk, RT
    Shields, P
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2001, 10 (03) : 261 - 263
  • [2] Is CYP2D6 phenotype predictable from CYP2D6 genotype?
    Kiss, Adam Ferenc
    Toth, Katalin
    Juhasz, Cintia
    Temesvari, Manna
    Paulik, Jozsef
    Hirka, Gabor
    Monostory, Katalin
    MICROCHEMICAL JOURNAL, 2018, 136 : 209 - 214
  • [3] A role for CYP2D6 in nicotine metabolism? Target article on nicotine-addiction
    Smith, G
    Sachse, C
    PSYCOLOQUY, 2001, 12 (05): : 1 - 10
  • [4] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [5] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    Gressier, F.
    Verstuyft, C.
    Hardy, P.
    Becquemont, L.
    Corruble, E.
    JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) : 35 - 42
  • [6] CONCORDANCE OF PHENOTYPE AND GENOTYPE FOR CYP2D6
    MCLEOD, HL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (04) : 463 - 463
  • [7] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    F. Gressier
    C. Verstuyft
    P. Hardy
    L. Becquemont
    E. Corruble
    Journal of Neural Transmission, 2015, 122 : 35 - 42
  • [8] Quantitative assessment of the effect of CYP2D6 genotype on tamoxifen metabolism: A model for CYP2D6 genotype-phenotype studies.
    Borges, S
    Desta, Z
    Jin, Y
    Li, L
    Skaar, TC
    Flockhart, DA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P34 - P34
  • [9] POOR METABOLIZERS OF NICOTINE AND CYP2D6 POLYMORPHISM
    CHOLERTON, S
    ARPANAHI, A
    MCCRACKEN, N
    BOUSTEAD, C
    TABER, H
    JOHNSTONE, E
    LEATHART, J
    DALY, AK
    IDLE, JR
    LANCET, 1994, 343 (8888): : 62 - 63
  • [10] CYP2D6 polymorphism in a Gabonese population:: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype
    Panserat, S
    Sica, L
    Gérard, N
    Mathieu, H
    Jacqz-Aigrain, E
    Krishnamoorthy, R
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (01) : 121 - 124